Welcome!

News Feed Item

/ CORRECTION - Corcept Therapeutics

CHICAGO, IL -- (Marketwired) -- 06/20/14 -- In the news release, "New Research on Corcept's Korlym® for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June 19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we are advised by the company that the session schedule has now been updated to reflect accurate presentation times with poster numbers added. Complete corrected text follows.

New Research on Corcept's Korlym® for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014

New Data Includes Results of a Long-Term Extension Phase of Corcept's Multicenter, Open-Label SEISMIC Study

CHICAGO, IL -- Jun 19, 2014 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).

The research, including results of a long-term extension phase of Corcept's multicenter, open-label SEISMIC study of Korlym, will be presented at the conference, taking place at the McCormick Place West Convention Center in Chicago from June 21-24. Korlym is a once-daily oral treatment for patients with Cushing's syndrome who have glucose intolerance and have failed or cannot have surgery.

"Cushing's syndrome, which is caused by excessive cortisol activity, is a serious condition that has a debilitating impact on all aspects of patients' lives. The disease often significantly affects patients' metabolism, leading to extreme weight gain with abnormal fat deposits, impaired glycemic control including type 2 diabetes, muscle weakness and, commonly, psychiatric symptoms," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Because Cushing's syndrome may be a chronic disease, it is important to monitor patients taking Korlym over time. The long-term extension study of SEISMIC includes data from patients who had been receiving treatment for as long as 3.5 years."

Cushing's syndrome is the result of excessive cortisol activity throughout the body. Cortisol is a hormone made in the adrenal glands that performs vital tasks such as regulating the metabolism of proteins, carbohydrates and fats. Cushing's syndrome afflicts 20,000 people in the United States, with approximately 3,000 to 4,000 new cases each year. Approximately half of these patients are cured by surgery.

The following abstracts highlight new research on mifepristone:


----------------------------------------------------------------------------
Date      Session   Poster    Title                           Authors
          Time      Number
----------------------------------------------------------------------------
Saturday, 11:30am-  OR02-2    Late-Night Salivary Cortisol    Ty Brian
 June 21, 1:00pm              for the Diagnosis of Recurrent  Carroll, MD;
 2014                         Cushing's Disease: Evidence of  Bradley R
                              Clinical Benefit from Early     Javorsky, MD;
                              Detection                       James W
                                                              Findling, MD
          ------------------------------------------------------------------
          1:00-     SAT-0671  Clinical Management in a Female Elizabeth E
          3:00pm              with Persistent Cushing's       King, MD;
                              Disease Treated with            Simone M
                              Mifepristone for Four Years     Howell, RN,
                                                              CCRA
----------------------------------------------------------------------------
Sunday,   1:00-     SUN-0750  Effect of Mifepristone on       Vijay Babu
 June 22, 3:00pm              Cushing's syndrome Secondary to Balakrishnan;
 2014                         Bilateral Adrenal Adenomas: A   Pankaj Sharda,
                              Case Presentation               MBBS, MD;
                                                              Elias Said
                                                              Siraj, MD
----------------------------------------------------------------------------
Monday,   1:00-     MON-0439  Improved Activities of Daily    Daphne T
 June 23, 3:00pm              Living, Normal Mood and Quality Adelman, BSN,
 2014                         of Life: 4 Years of Treatment   MBA; Simone M
                              Data in a Premenopausal Woman   Howell, RN,
                              with Cushing's Disease          CCRA


                    --------------------------------------------------------
                    MON-0592  A Case Report of a 37 y/o Woman Howard A
                              Diagnosed with Cushing's        Brand, MD;
                              Disease Presenting As Pituitary Kimberly
                              Apoplexy after Multiple         Calcagno, MA;
                              Treatment Failures Effectively  Michele
                              Responds to Mifepristone        Lamerson, RN,
                                                              MS, CPNP
                    --------------------------------------------------------
                    MON-0595  Discontinuation of Insulin,     Kevin C.J.
                              Oral Antidiabetic and           Yuen, MD, FRCP
                              Antihypertensive Medications in (UK); Harold I
                              a Patient with Cushing's        Magazine, PhD
                              Disease Following Mifepristone
                              (MIFE) Therapy
                    --------------------------------------------------------
                    MON-0598  Mifepristone for Refractory     Audrey
                              Cushing's Syndrome in a Patient Elisabeth
                              with CKD Hyperkalemia           Arzamendi, MD;
                              Undergoing Surgical Exodontia   Alison Marie
                              and Weight Loss:                Semrad, DO
                              Recommendations for
                              Clinical/Biochemical Monitoring
                              and Perioperative Dosing
                    --------------------------------------------------------
                    MON-0663  Persistent Weight Loss in       Henry G. Fein,
                              Patients Treated with           MD; T. Brooks
                              Mifepristone (MIFE) for         Vaughan III,
                              Cushing's Syndrome: Results     MD; Coleman
                              from the Seismic & Long Term    Gross; Dat
                              Extension Studies               Nguyen
----------------------------------------------------------------------------

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that regulate the effects of the stress hormone cortisol on the body. The FDA has approved the company's first drug, Korlym® (mifepristone) 300 mg Tablets, a glucocorticoid receptor antagonist, as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Corcept is exploring mifepristone (the active ingredient in Korlym) as a treatment for triple-negative breast cancer with a multi-center, Phase I clinical study currently underway in patients with metastatic or locally advanced unresectable breast cancer. It is also supporting investigator-led clinical studies of mifepristone in the treatment of ovarian cancer and castration-resistant prostate cancer. The company has a portfolio of selective glucocorticoid-receptor (GR) antagonists that block the effects of cortisol but not progesterone. It owns or has licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders and triple-negative breast cancer. It also holds composition of matter patents for its selective GR antagonists.

Investor Contact
Charles Robb
Corcept Therapeutics Incorporated
Chief Financial Officer
Email Contact
650-688-8783

Media Contact
Brian Baxter for Corcept
Lazar Partners Ltd.
Email Contact
646-871-8491

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Pentaho has announced orchestration capabilities that streamline the entire machine learning workflow and enable teams of data scientists, engineers and analysts to train, tune, test and deploy predictive models. Pentaho’s Data Integration and analytics platform ends the ‘gridlock’ associated with machine learning by enabling smooth team collaboration, maximizing limited data science resources and putting predictive models to work on big data faster – regardless of use case, industry, or languag...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
SYS-CON Events announced today that Addteq will exhibit at SYS-CON's DevOps Summit at Cloud Expo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Addteq specializes in creating innovative solutions to solve business processes through the use of DevOps automation. Addteq was founded on the firm belief that automation is essential for successful software releases. Addteq's products and services are centered around the fundamental approach of understanding the pr...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Peak 10 has announced that it has completed a 20,000 square foot expansion of its Cincinnati-area data center, a 6,000 square foot expansion of its data center campus in Charlotte’s University Research Park, and added a pair of seasoned executives to its leadership team. This further propels the company on its aggressive growth trajectory to meet the rising demand for flexible hybrid IT strategies and solutions across its enterprise customer base. Cincinnati is home to companies like Kroger, Pr...
VeriStor Systems has announced that CRN has named VeriStor to its 2017 Managed Service Provider (MSP) 500 list in the Elite 150 category. This annual list recognizes North American solution providers with cutting-edge approaches to delivering managed services. Their offerings help companies navigate the complex and ever-changing landscape of IT, improve operational efficiencies, and maximize their return on IT investments. In today’s fast-paced business environments, MSPs play an important role...
SYS-CON Events announced today that Infranics will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Since 2000, Infranics has developed SysMaster Suite, which is required for the stable and efficient management of ICT infrastructure. The ICT management solution developed and provided by Infranics continues to add intelligence to the ICT infrastructure through the IMC (Infra Management Cycle) based on mathemat...
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...